Frederick, MD –
On July 24, 2024, the Department of Defense (DOD) fulfilled the final Fiscal Year (FY) 2024 delivery of 626,870 doses of the U.S. Food and Drug Administration (FDA)-approved BioThrax® (Anthrax Vaccine Adsorbed), a pre-exposure prophylaxis (PrEP) for anthrax disease. This marks the completion of the first annual delivery – part of a larger procurement contract – which showcases the DOD’s ongoing commitment to vaccine readiness for active-duty service members to support mission needs.
Led by the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), on behalf of the DOD and the Defense Health Agency, the $235.8 million, 10-year, sole source, indefinite delivery/indefinite quantity (ID/IQ) contract with Emergent Biosolutions, Inc. was awarded on January 09, 2024, for use by all branches of service over the next 10 years.
“This award was the result of an immense effort by the JPEO-CBRND and Army Contracting Command – Edgewood team who worked feverishly for 14 months preparing the contract packet, establishing a Vendor Managed Inventory (VMI) partner, and establishing an order fulfillment mechanism through the U.S. Army Medical Materiel Agency Distribution Operations Center,” said COL Matthew Clark, Joint Project
Manager for the Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical), a component of the JPEO-CBRND. “Fulfillment of this first annual procurement requirement highlights our shared commitment in continuing to provide a layered defense against threats like anthrax to the warfighter.”
On July 24, 2024, the last shipment of BioThrax® (AVA) for FY24 was received at the VMI facility. Pictured Right to Left: Betty Janouris, Theresa Wunder, Stephanie Murtha, Bob Murtha, Billy Dobbs, Breena Berté, Max Jones, Kevin Watts.
The BioThrax® vaccine is indicated for the active immunization for the prevention of disease caused by Bacillus anthracis in persons 18 through 65 years of age, as well as for PrEP in persons at high risk of exposure. It is also approved for post-exposure prophylaxis (PEP) of disease following suspected or confirmed Bacillus anthracis exposure, when administered in conjunction with recommended antibacterial drugs.
###
About the JPEO-CBRND: The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) mission is to provide an integrated layered chemical, biological, radiological, and nuclear defense capabilities to the joint force across combined Joint All-Domain Operations. JPEO-CBRND’s goal is to enable the joint force to fight and win unencumbered by a CBRN environment. To learn more about JPEO-CBRND, visit: https://www.jpeocbrnd.osd.mil/, or follow JPEO-CBRND on social media @JPEOCBRND.
About the JPM CBRN Medical: The Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical), a component of the U.S. Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, aims to provide U.S. military forces and the nation with safe, effective, and innovative medical solutions to counter chemical, biological, radiological, and nuclear threats. The JPM CBRN Medical facilitates the advanced development and acquisition of medical countermeasures and systems to enhance the nation’s biodefense response capability.
Disclaimer: The views and opinions expressed herein to any specific commercial products, process, or service by trade name, trademark, manufacturer, or otherwise do not necessarily constitute or imply endorsement, recommendation, or favoring by the United States government and shall not be used for advertising or product endorsement purposes.